Commentary on “It is time to share Alzheimer biomarker results in dementia with Lewy bodies”

Many people with dementia with Lewy bodies (DLB) have evidence of Alzheimer's disease (AD) co-pathology, which can be assessed in vivo using biomarkers. In this issue, Armstrong and colleagues argue that it is now timely to disclose such AD biomarker results to people with DLB. They provide logical and powerful arguments, including the right for people to know and the value of this information in informing outcome and management. However, there are also important caveats to consider and a careful balance needs to be maintained between, on the one hand, the right to know and convey clinically useful information and, on the other, acknowledging the real uncertainty that exists regarding the true diagnostic and management implications of AD biomarkers in an individual with a DLB rather than an AD clinico-pathological syndrome.